Background
Methods
Aim
Study design
Setting
Study population
Outcomes and data
Covariates
Statistical analysis
Results
Ovarian cancer or borderline ovarian tumour | No cancer | Total | ||||
---|---|---|---|---|---|---|
Median | (IQR) | Median | (IQR) | Median | (IQR) | |
Age at index date | 66 | (57; 74) | 66 | (57; 74) | 66 | (57; 74) |
N | (%) | N | (%) | N | (%) | |
Total | 4,255 | (100.0) | 42,550 | (100.0) | 46,805 | (100.0) |
Sex | ||||||
Female | 4,255 | (100.0) | 42,550 | (100.0) | 46,805 | (100.0) |
Age groupsa, years | ||||||
40–49 | 500 | (11.8) | 4,995 | (11.7) | 5,495 | (11.7) |
50–64 | 1,384 | (32.5) | 13,835 | (32.5) | 15,219 | (32.5) |
65–74 | 1,344 | (31.6) | 13,445 | (31.6) | 14,789 | (31.6) |
75–84 | 785 | (18.4) | 7,891 | (18.5) | 8,676 | (18.5) |
85+ | 242 | (5.7) | 2,384 | (5.6) | 2,626 | (5.6) |
Comorbidityb | ||||||
None | 3,346 | (78.6) | 32,539 | (76.5) | 35,885 | (76.7) |
Low | 782 | (18.4) | 8,495 | (20.0) | 9,277 | (19.8) |
High | 127 | (3.0) | 1,516 | (3.6) | 1,643 | (3.5) |
Educational levelc | ||||||
Short | 1,551 | (36.5) | 16,052 | (37.7) | 17,603 | (37.6) |
Medium | 1,687 | (39.6) | 16,895 | (39.7) | 18,582 | (39.7) |
Long | 1,017 | (23.9) | 9,603 | (22.6) | 10,620 | (22.7) |
Disposable incomed | ||||||
Low | 1,362 | (32.0) | 14,084 | (33.1) | 15,446 | (33.0) |
Middle | 1,457 | (34.2) | 13,988 | (32.9) | 15,445 | (33.0) |
High | 1,436 | (33.7) | 14,478 | (34.0) | 15,914 | (34.0) |
Marital statusd | ||||||
Cohabitant | 2,301 | (54.1) | 23,877 | (56.1) | 26,178 | (55.9) |
Living alone | 1,954 | (45.9) | 18,673 | (43.9) | 20,627 | (44.1) |
Country of origin | ||||||
Danish | 4,029 | (94.7) | 39,827 | (93.6) | 43,856 | (93.7) |
Immigrant | 226 | (5.3) | 2,723 | (6.4) | 2,949 | (6.3) |
Tumour stagee | ||||||
I | 1,416 | (33.3) | n/a | n/a | 1,416 | (3.0) |
II | 245 | (5.8) | n/a | n/a | 245 | (0.5) |
III | 1,245 | (29.3) | n/a | n/a | 1,245 | (2.7) |
IV | 972 | (22.8) | n/a | n/a | 972 | (2.1) |
Unknown | 377 | (8.9) | n/a | n/a | 377 | (0.8) |
Reference | n/a | n/a | 42,550 | (100.0) | 42,550 | (90.9) |
General practice
Month − 12 to -6.5 | Month − 6.5 to -2 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases | References | Cases | References | |||||||||
n | (%) | n | (%) | RR | 95% CI* | n | (%) | n | (%) | RR | 95% CI* | |
All | 4,255 | (100) | 42,550 | (100) | 4,255 | (100) | 42,550 | (100) | ||||
Consultations | ||||||||||||
0 | 1,223 | (28.74) | 11,856 | (27.86) | 1.02 | 0.97–1.07 | 712 | (16.73) | 11,649 | (27.38) | 0.60 | 0.56–0.65 |
1–4 | 2,304 | (54.15) | 23,292 | (54.74) | 0.99 | 0.96–1.02 | 2,416 | (56.78) | 23,528 | (55.29) | 1.03 | 1.00-1.06 |
5–8 | 548 | (12.88) | 5,528 | (12.99) | 1.01 | 0.93–1.10 | 853 | (20.05) | 5,540 | (13.02) | 1.56 | 1.46–1.66 |
≥9 | 180 | (4.23) | 1,874 | (4.40) | 1.01 | 0.87–1.17 | 274 | (6.44) | 1,833 | (4.31) | 1.56 | 1.38–1.76 |
Hb measurements | ||||||||||||
0 | 3,766 | (88.51) | 37,641 | (88.46) | 1.00 | 0.99–1.01 | 3,495 | (82.14) | 37,667 | (88.52) | 0.93 | 0.92–0.94 |
≥1 | 489 | (11.49) | 4,909 | (11.54) | 1.01 | 0.94–1.10 | 760 | (17.86) | 4,883 | (11.48) | 1.57 | 1.48–1.68 |
Urine dipstick tests | ||||||||||||
0 | 3,686 | (86.63) | 37,227 | (87.49) | 0.99 | 0.98-1.00 | 3,164 | (74.36) | 37,114 | (87.22) | 0.85 | 0.84–0.87 |
≥1 | 569 | (13.37) | 5,323 | (12.51) | 1.09 | 1.01–1.18 | 1,091 | (25.64) | 5,436 | (12.78) | 1.99 | 1.88–2.10 |
Blood tests | ||||||||||||
0 | 3,022 | (71.02) | 30,070 | (70.67) | 1.00 | 0.99–1.02 | 2,523 | (59.29) | 29,433 | (69.17) | 0.86 | 0.84–0.88 |
≥1 | 1,233 | (28.98) | 12,480 | (29.33) | 1.01 | 0.96–1.05 | 1,732 | (40.71) | 13,117 | (30.83) | 1.31 | 1.26–1.36 |